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Abstract
Background and objectives: Noroviruses (NoVs) are major causative agents of non-bacterial acute
gastroenteritis in people of all ages worldwide. NoV capsid VP1 derived virus-like particles (VLPs) produced in
various expression systems are main vaccine candidates against NoV. The aim of this study was to investigate and
compare systemic and mucosal delivery and a combination of both deliveries of NoV VLPs for induction of immune
responses in BALB/c mice.
Materials and methods: BALB/c mice were immunized Intramuscularly (IM), Intranasally (IN) or sequentially (IM
followed by IN) with a candidate NoV GII-4 VLP vaccine developed by our laboratory. NoV GII-4-specific serum and
mucosal IgG and IgA antibodies were analyzed by ELISA. GII-4–specific T cell immune responses were investigated
using an ELISPOT assay measuring production of interferon-γ (IFN-γ) at a single cell level.
Results: IM immunized mice developed a strong systemic and mucosal NoV-specific IgG antibody response but
completely lacked IgA response. In contrast, mice immunized IN had strong systemic and mucosal IgG and IgA
production but lacked CD8+ T cell responses. Sequential immunization compensated for the deficient IgA and CD8+
T cell responses induced by each delivery alone.
Conclusion: Our results show that sequential IM+IN immunization should be considered for NoV VLP vaccine
delivery to activate broad immune responses.
Keywords: Noroviruses; Vaccine; Immune Response
Introduction
Noroviruses (NoV) are the leading cause of non-bacterial acute
gastroenteritis (AGE) in people of all ages. NoV infections are
responsible for over a million hospitalizations and up to 200,000
deaths annually in infants and children of developing countries [1].
After introduction of rotavirus vaccines in the USA, Finland, and
other countries, NoVs have become the leading cause of medically
attended AGE in children under five years of age [2,3]. Therefore,
young children are an important target group for future NoV
vaccination. NoVs are highly contagious and cause large outbreaks in
community setting such as nursing homes, childcare facilities,
military, and cruise ships.
NoV genogroups GI and GII are responsible for most infections in
humans with GII-4 genotype being predominant for more than two
decades [4,5]. After expression in vitro major NoV capsid protein self-
assembles into virus-like particles (VLPs) consisting of 90 dimers of
VP1 [6]. These VLPs are morphologically and functionally similar to
the native virus but lack genetic material.
Human NoVs are uncultivable in vitro and, therefore, development
of conventional vaccines based on live attenuated or killed NoVs is not
possible at present time. Instead, NoV VLPs have been proposed as
vaccine candidates against NoVs. As NoV is an enteric pathogen that
uses intestinal mucosa as a port of entry, most of the immunogenicity
studies in animals [7,8] as well as early phase clinical trials [9-11] have
used mucosal immunization (oral or intranasal; IN) for delivery of
NoV VLPs. More recently, intramuscular (IM) delivery has been
considered [12-14].
Correlates of protection to NoV infection are largely unknown.
Histo-blood group antigens (HBGAs) are cellular attachment factors
or receptors for NoVs [15]. These complex carbohydrates are present
on the surface of enteric mucosal cells as well as free antigens in body
secretions. Serum antibodies, which block binding of VLPs to the
HBGAs, are considered as a surrogate of neutralizing antibodies and
correlates of protection to NoV infection [16-19].
Other studies have also suggested important role of cellular and
mucosal immunity against NoV infection and gastroenteritis [20-22].
In this study we compared induction of potentially protective immune
responses induced with NoV VLPs by systemic IM or mucosal IN
immunization as well as sequential immunization (IM followed by IN)
in BALB/c mice. To date, there have been no studies using combined
systemic and mucosal delivery approaches with NoV VLPs. Our
results show that sequential IM+IN immunization compensated for
deficient NoV-specific serum IgA and T cell responses induced by IM
and IN delivery alone.
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Materials and Methods
Immunization of experimental animals and sample
collection
To analyze NoV GII-4 VLP induced immune responses 10 female
BALB/c OlaHsd mice (7 weeks old; Harlan Laboratories, The
Netherlands) were immunized at day 0 and day 21 with a NoV VLP
and rotavirus VP6 combination vaccine candidate developed by our
laboratory [12,23] containing 10 µg GII-4 VLPs by IM or IN route.
The immunogen was administered in a 50 µl volume sterile
phosphate-buffered saline (PBS) into quadriceps femoris or in a 25 µl
volume by gradual inoculation in each nostril. In addition, a group of
mice was primed with the combination vaccine containing 10 µg NoV
GII-4 VLPs by IM route at day 0 and boosted by IN route at day 21,
termed sequential immunization. Naïve mice receiving carrier only
(sterile PBS) either by IM or IN route were used as negative controls.
Mice were terminated two weeks after the final immunization (day 35)
and blood, feces and spleen were collected as described previously
[24,25]. All procedures were performed in accordance with the
regulations and guidelines of the Finnish Animal Experiment Board.
Serum antibody ELISA
Individual mouse sera were serially diluted starting at 1:200 and
tested for NoV GII-4 specific total IgG antibodies in an ELISA assay as
previously described [23]. Briefly, 96-well plates (Corning Inc.
Corning, NY) were coated with 50 ng/well of GII-4 VLPs in PBS and
bound antibodies detected with HRP-conjugated goat anti-mouse IgG
(Sigma-Aldrich). Groupwise pooled sera of each experimental group
was 2-fold serially diluted (starting at a 1:20 dilution) and tested for
GII-4 specific IgA antibodies using HRP-conjugated goat anti-mouse
IgA (Sigma-Aldrich) at a dilution of 1:4000. Optical density (OD) at
490 nm was measured by Victor2 1420 reader (Perkin Elmer) and a
sample was considered positive if the OD was above the mean OD of
control mice +3SD. End-point titers were expressed as the highest
serum dilution giving a positive reading. Sera of each mouse at a
dilution 1:200 were tested for IgG antibody avidity using ELISA as
described above with an extra urea incubation step [19,26] where
antibodies bound to GII-4 VLP coated plates were treated twice with
8M urea before addition of HRP-conjugated anti-mouse IgG. Avidity
index was calculated as (OD with urea/OD without urea) × 100%.
Mucosal antibody ELISA
Faecal droplets from each mouse were pooled and 10% stool
suspensions were made as earlier described in details [12]. Stool
suspensions were serially 2-fold diluted starting at 1:5 and tested for
NoV GII-4-specific IgG and IgA with the ELISA as described above.
Serum antibody blocking assay
Human type A saliva from a secretor positive individual and
synthetic biotinylated H-type-3 carbohydrate were used as a source of
HBGAs in blocking assays. Saliva blocking assay was performed
essentially as earlier described by our laboratory [23]. 96-well plates
were coated with saliva type A at a 1:3000 dilution and incubated
overnight at 37°C. For synthetic HBGA blocking assay SuperBlock
pretreated High Binding Capacity NeutrAvidin plates (Pierce) were
incubated with 2.5 µg/ml of the synthetic biotinylated H (type 3)-
PAA-Biotin (Glycotech) for 1 hour at room temperature [27]. GII-4
VLPs were pre-incubated with serially two-fold diluted (1:100–1:3200)
experimental and control mouse sera for 1 h at 37°C and added to the
saliva or H-type-3 coated plates. Saliva plates were further incubated
for 1.5 hour at 37°C and NeutrAvidin plates for 2 hour at +4°C. The
bound VLPs were detected with NoV antibody positive human serum
and anti-human IgG-HRP (Invitrogen) followed by the OPD
substrate. VLPs lacking the serum were used as the maximum binding
control. The blocking index (%) was calculated as 100% – (OD wells
with VLP serum mix/OD wells without serum; maximum binding) ×
100%.
Cell mediated immune response
NoV GII-4-specific T cell responses were measured with an
ELISPOT assay by quantification of interferon (IFN)-γ producing
splenocytes [25].
Multiscreen 96-well HTS-IP filter plates (Millipore) were coated
with anti-mouse IFN-γ antibody AN18 (2.5 µg/ml, Mabtech).
Splenocytes (0.1×106/well) from the experimental or control mice
were stimulated with a GII-4 capsid derived 15-mer synthetic peptide
named NP-4 at 5 µg/ml (ProImmune Ltd., amino acids
CLLPQEWVQHFYQEA) or GII-4 VLPs at 2.5 µg/ml. Cells incubated
in culture media alone and cells stimulated with 10 µg/ml Concavalin
A (ConA, Sigma-Aldrich) served as a background and cell viability
controls.
After overnight incubation at 37°C IFN-γ secretion was detected
with biotinylated anti-mouse IFN-γ antibody R4-6A2 (2.5 µg/ml,
Mabtech) and streptavidin-ALP (Mabtech). The spots developed with
BCIP/NBT substrate (Mabtech) were counted by ImmunoSpot®
automatic CTL analyzer (CTL-Europe GmbH). The results are
expressed as mean spot forming cells (SFC)/106 cells of duplicate wells.
To determine which cell type is responsible for the IFN-γ
production, splenocytes were preincubated (1 hour at 37°C) with the
functional blocking antibodies rat anti-mouse CD4 or rat anti-mouse
CD8 (both from eBiosciences) at a 30 µg/ml concentration prior to
stimulation with the GII-4-specific peptide or GII-4 VLPs.
Statistical analyses
Fisher’s exact test was used for comparison of GII-4 VLP-specific
IgG endpoint titers. P<0.05 was considered statistically significant. All
hypothesis testing was two-tailed.
Results
Serum NoV-specific antibody responses
Serum GII-4-specific IgG titers of individual mice immunized at
day 0 and day 21 with a candidate vaccine containing 10 µg NoV GII-4
VLPs by IM or IN delivery route are shown in Figures 1A and 1B.
Regardless of the delivery route each mouse developed a strong IgG
antibody response with endpoint titers of 5log10 (p>0.05).
In all of the sera the GII-4 specific IgG antibodies had high avidity
with an avidity index >50% (Figure 1C). As these results indicated
uniform success of immunization of each mouse in the experimental
group, the sera were pooled groupwise and GII-4 specific IgA titers
were determined by ELISA (Figure 1D). IN immunized mice
generated a remarkable serum IgA antibody response (mean OD 0.40,
titer 1:20) while IM immunized mice did not (mean OD 0.07, titer
1:20).
Citation: Malm M, Tamminen K, Vesikari T, Blazevic V (2015) Comparison of Intramuscular, Intranasal and Combined Administration of
Norovirus Virus-Like Particle Subunit Vaccine Candidate for Induction of Protective Immune Responses in Mice. J Clin Cell Immunol 6:
284. doi:10.4172/2155-9899.1000284
Page 2 of 7
J Clin Cell Immunol
ISSN:2155-9899 JCCI, an open access journal Volume 6 • Issue 1 • 1000284
Figure 1: NoV GII-4-specific serum antibody responses in BALB/c mice. Mice (10 mice/group) were immunized twice (at day 0 and day 21)
with a NoV vaccine candidate containing 10 µg GII-4 VLPs. (A) Termination sera of intramuscularly (IM) immunized mice was assayed for
NoV GII-4-specific IgG with two-fold dilutions starting at 1:200. Shown are individual titration curves of each immune sera and titration
curve of pooled control mice sera (6 mice/group) immunized with the carrier (PBS) only (dashed line). (B) GII-4-specific IgG titration curves
of intranasally (IN) immunized mice and pooled control mice sera. (C) Avidity of GII-4-specific IgG antibodies of each immunized mouse
was analyzed in modified ELISA assay at a dilution of 1:200 as described in the Materials and Methods. Shown is avidity index ((OD with
urea/OD without urea) x 100) of each mouse sera and the mean of the group. Dashed line indicates the cut-off for high avidity antibodies
(>50%). (D) GII-4-specific serum IgA titers were assayed with two-fold dilutions (starting at a 1:20) of group wise pooled serum. Shown are
mean OD values of the IM, IN and corresponding control mouse groups with the standard errors of the mean (SEM) of the replicates.
Mucosal IgG and IgA antibodies
Groupwise pooled fecal samples of IM and IN immunized mice
were tested for GII-4 specific IgG and IgA antibody content. Both
delivery routes induced similar levels of IgG antibodies in the
intestines (mean OD 0.57 for IM and mean OD 0.48 for IN, titer 1:50)
(Figure 2A). Similar to the serum samples (Figure 1D, respectively),
mice immunized with NoV GII-4 VLP by IM delivery did not develop
intestinal IgA antibodies (mean OD 0.04, titer 1:5) (Figure 2B) while
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mucosal IN delivery induced considerable level of intestinal IgA
antibodies (mean OD 0.49, titer 1:5) (Figure 2B).
Figure 2: NoV GII-4-specific mucosal antibody responses in
BALB/c mice. Mice were immunized twice with a NoV vaccine
candidate containing 10 µg GII-4 VLPs. Intestinal IgG (A) and IgA
(B) antibodies were analyzed from 10% fecal suspensions of IM and
IN immunized mice (solid lines) or the control mice (dashed lines).
Fecal samples of five mice/experimental group were pooled for
analysis. Shown are mean ODs with the standard errors of the
mean (SEM) of two independent experiments.
Figure 3: Blocking of NoV GII-4 VLP binding to the HBGA
receptors by immune mouse sera. Group wise pooled (five mice/
group), two-fold diluted sera of mice immunized by IM or IN route
with a NoV vaccine candidate containing 10 µg GII-4 VLPs were
assayed for blocking activity. Corresponding control group serum
was used as a non-specific blocking control. (A) Blocking of GII-4
VLP binding to human secretor positive saliva type A. (B) Blocking
of GII-4 VLP binding to the H-t-3 synthetic HBGA. The blocking
index (%) was calculated as 100% - (OD wells with serum/OD wells
without serum, a maximum binding) × 100%. Results are shown as
the mean blocking index of duplicate wells with similar results from
a minimum of two independent experiments.
Blocking ability of NoV-specific antibodies
Sera of GII-4 VLPs immunized and control mice were pooled
groupwise and tested for blocking of GII-4 VLP binding to human
type A saliva (Figure 3A) and synthetic H-type-3 carbohydrate (Figure
3B). Both IM and IN immunization induced strong blocking
antibodies in the sera with 100% blocking up to a dilution 1:800 in the
saliva blocking assay (Figure 3A). Blocking of the GII-4 VLPs’ binding
to the synthetic H-type-3 was used to confirm the results of the saliva
blocking assay (Figure 3B). Both immunizations induced comparable
blocking responses in the sera, which correlated to the blocking
responses seen in the saliva assay. Neither of the control groups’ (ctrl
IM or ctrl IN, respectively) sera contained antibodies able to block
GII-4 VLP binding to the HBGAs (Figure 3A and 3B).
Figure 4: NoV GII-4-specific interferon-γ (IFN-γ responses. (A)
Splenocytes of mice immunized by IM or IN route with a NoV
vaccine candidate containing 10 µg GII-4 VLPs or control mice
receiving PBS were stimulated in vitro with GII-4 capsid derived
15-mer peptide (NP-4) or with the homologous GII-4 VLPs. IFN-γ
production at a single cell level was detected by an ELISPOT assay.
(B) T cell restriction of the NoV GII-4-specific IFN-γ production.
Cells were stimulated with the NP-4 peptide or GII-4 VLPs in the
presence or absence of CD4 and CD8 specific antibodies to block
the T cell activation. Results are expressed as the mean Spot
Forming Cells (SFC)/106 cells of at least two independent
experiments with standard errors.
NoV GII-4-specific CD8+ T cell responses
NoV GII-4-specific T cell responses measured by IFN-γ production
at a single cell level in ELISPOT assay were different in mice
immunized by IM or IN route. IM immunized mice had high
frequency of IFN-γ producing cells in spleen in response to the GII-4
capsid derived 15-mer peptide NP-4 (438 ± 119 SFC/106 cells) while
IN immunized mice completely lacked these responses, as did the the
control mice (Figure 4A). The T cell responses were also tested using
NoV GII-4 VLPs as an in vitro stimuli and comparable responses were
detected in mice immunized by IM (140 ± 40 SFC/106 cells) and IN
delivery route (156 ± 42 SFC/106 cells) (Figure 4A). In order to
determine which T cells responded to the peptide and GII-4 VLPs,
blocking antibodies to CD4 and CD8 cell surface antigens were used to
show the restriction of the NoV GII-4-specific IFN-γ responses
(Figure 4B). The T cell responses to the NP-4 peptide were only
blocked by anti-CD8 antibody (mean 68 % inhibition), while GII-4
VLP responses were blocked by anti-CD4 antibody only (mean 77%
inhibition). These results indicate impaired functionality of CD8+ T
cells in mice immunized by IN delivery in contrast to IM immunized
mice. Furthermore, the results also show that both delivery routes
induced functional CD4+ T cells by responding to GII-4 VLPs.
Immune responses by sequential immunization
As IM and IN immunizations alone induced deficient immune
responses we next combined the two to determine combined effect of
the delivery routes. Immunization of mice with NoV GII-4 VLPs first
IM (at day 0) and sequentially IN (at day 21) induced serum and
mucosal GII-4 specific IgA antibodies (Figure 5A) and NP-4 peptide
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specific CD8+ T cell IFN-γ responses (Figure 5B) comparable to the
optimal responses induced by each route separately (Figure 1D, 2B
and 4A respectively). Serum and fecal GII-4 specific IgG antibodies as
well as blocking antibody activity were comparable to each route
separately as well. Serum GII-4 IgG endpoint titer was 102400 and the
mean avidity index was 94.5 ± 0.2 %. Serum dilution of 1:800 blocked
92% of GII-4 VLP binding in the saliva blocking assay.
Figure 5: NoV GII-4-specific humoral and cell-mediated immune
responses induced by sequential immunization. Group of mice
were immunized with a NoV vaccine candidate containing 10 µg
GII-4 VLPs at day 0 by IM delivery and day 21 by IN delivery. (A)
NoV GII-4-specific IgA antibodies were analyzed from serum and
fecal suspensions. Serum samples were two-fold diluted starting at a
1:20 dilution and 10% fecal suspension were analyzed starting at a
1:2 dilution. Shown are mean ODs with standard errors of the
replicates. (B) NoV GII-4-specific IFN-γ responses after
stimulating the splenocytes with GII-4 capsid derived 15-mer
peptide (NP-4) or culture media (CM) only. Shown are the mean
spot forming cells (SFC)/106 cells of the individually tested mice
with the standard errors.
Discussion
NoV VLPs are excellent vaccine candidates as they resemble native
virions morphologically and antigenically and are highly
immunogenic [6], in addition to being safe. NoV VLPs can be given by
mucosal delivery orally or IN, or parenterally (IM or intradermally,
ID). As NoV is an orally transmitted enteric pathogen and natural
immunity to NoV is of a short duration [28-30] it remains to be
determined if systemic immunization with NoV VLP vaccine might be
a better choice than mucosal one to induce long lasting protective
immunity. In here we studied different delivery of NoV VLP vaccine
by comparing immune responses induced by IN and IM
immunization. Our results indicate that there are inherent differences
in immune system activation by NoV VLPs administered systemically
or mucosally.
We have previously shown that systemic delivery (IM and ID) of
NoV VLPs either alone or in a combination with rotavirus VP6
protein induces robust humoral and cell mediated immune responses
specific for NoV [12,23,25]. The results in this study confirm the
earlier findings that IM immunization with GII-4 VLPs induces both
IgG antibody and T cell responses (CD4+ and CD8+, respectively) but
in addition show the absence of serum and mucosal IgA although
significant levels of IgG were detected in the gut mucosa. Transfer of
serum IgG into the gut lumen is likely an important protective
mechanism against gut infection [31]. On the contrary, IN delivery
induced similar IgG antibody responses to NoV in the serum and the
gut as observed with IM delivery, but the T cell responses, specifically
CD8+ T cells, were deficient. Velasquez et al. [8] have shown low levels
of IgG2a antibodies (a marker of a Th1 type immune response) by IN
delivery of NoV VLPs which is in a support of our findings. The
importance of T cells in NoV infection is not well known and there is a
limited number of studies addressing cellular immunity [21,22,32]. It
is believed that in contrast to live viral vaccines subunit protein
vaccines require T cells to induce protection [33]. In general, CD8+ T
cells, namely cytotoxic T lymphocytes (CTL), are critical for clearance
of virally infected cells [34,35]. A direct evidence for the role of T cells
in NoV infection comes from a study of murine norovirus (MNV)
showing that CD8+ and CD4+ T cells cleared infection in mice [36].
IN delivery of NoV GII-4 VLPs in this study induced high systemic
and mucosal GII-4 specific IgA antibodies. Contradictory findings are
related to the role of NoV-specific mucosal immunity. Lindesmith et
al. [20] reported a significant role for mucosal immunity, especially
salivary IgA in a protection from infection. On the contrary, other
researchers have reported insignificant role of serum IgA and
intestinal IgA in a chimpanzee model of a NoV infection [37] and
natural infection in young children [30]. Comparable level of
blocking/neutralizing activity of serum derived from IM and IN
immunized mice that were detected in this study (Figure 3,
respectively) would also suggest a negligible role for serum IgA
antibodies, as IgA was detected only in sera of IN immunized animals.
Two human challenge studies have been published recently in
subjects immunized with candidate NoV VLP vaccines administered
IN [16] and IM [14]. Interestingly, IN delivery of GI.1 VLP vaccine
(with an adjuvant) resulted in significant protection against
homologous NoV infection [16], whereas IM delivery of GII.4 vaccine
did not [14]. However, IM immunized subjects had significant
protection against severe NoV gastroenteritis [14]. These results
suggest different mechanism of protection against NoV infection,
induced by IN and IM immunization, respectively. Protection against
NoV infection requires immunity at the mucosal surfaces whereas
protection against the severe disease may require different mediators
for protection. Our findings in mice may shed light on the
interpretation of the results of the human challenge studies.
Our results show that sequential IM+IN immunization of mice with
NoV GII-4 VLPs compensate for deficiencies resulting from IM and
IN deliveries alone. This schedule was chosen as immunogenicity
studies of hepatitis B surface antigen in mice [38] showed that the
strongest systemic immune response associated with a strong mucosal
response was induced by IM prime followed by IN boost and not vice
versa. Sequential immunization induced GII-4 specific T cells of both
phenotypes (CD4+ and CD8+) and IgA antibodies in serum and
mucosa. It is possible that external adjuvant in combination with NoV
VLP vaccine might direct immune response in a desirable pathway.
However, in vaccine development in general, NoV VLP vaccine
without an adjuvant would be preferred particularly for use in
children. It remains to be determined why there is no induction of
effector CD8+ T cells producing IFN-γ after IN delivery of NoV VLPs.
It may be that these cells are activated at the mucosal delivery site but
do not disseminate to secondary lymphoid tissue, as has recently been
suggested [39,40].
Our laboratory has worked on the development of NoV and
rotavirus combination vaccine against the two most devastating
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enteric pathogens in children [12,23]. As natural immunity to NoV is
of a short duration, we postulated that IM immunization might induce
stronger and more durable immune responses than mucosal delivery
[13]. The results in this study show remarkable differences in the
immune responses induced by IM and IN delivery of NoV VLPs in
mice; absence of mucosal immunity, specifically intestinal IgA in IM
immunized mice and lack of NoV-specific CD8+ T cell immune
responses by IN delivery. It remains to be determined which responses
are relevant to protection against NoV infection and/or disease and
therefore for choosing of the route of NoV VLP vaccine delivery.
Before the exact correlates of protection are identified, sequential
immunization might be a good choice to ensure that different
effectors/mediators of the immune response are activated.
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